Your browser doesn't support javascript.
loading
What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
Latorraca, Carolina de Oliveira Cruz; Pacheco, Rafael Leite; Martimbianco, Ana Luiza Cabrera; Pachito, Daniela Vianna; Discipline of Evidence-Based MedicineRiera, Rachel.
Afiliação
  • Latorraca, Carolina de Oliveira Cruz; Universidade Federal de São Paulo. Evidence-Based Health Program. São Paulo. BR
  • Pacheco, Rafael Leite; Universidade Federal de São Paulo. Evidence-Based Health Program. São Paulo. BR
  • Martimbianco, Ana Luiza Cabrera; Universidade Metropolitana de Santos. Health and Environment Program. São Paulo. BR
  • Pachito, Daniela Vianna; Universidade Federal de São Paulo. Evidence-Based Health Program. São Paulo. BR
  • Discipline of Evidence-Based MedicineRiera, Rachel; Universidade Federal de São Paulo. Escola Paulista de Medicina. Discipline of Evidence-Based MedicineRiera, Rachel. São Paulo. BR
São Paulo med. j ; São Paulo med. j;136(5): 472-478, Sept.-Oct. 2018. tab
Article em En | LILACS | ID: biblio-979377
Biblioteca responsável: BR1.1
ABSTRACT
ABSTRACT

BACKGROUND:

The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach. DESIGN AND

SETTING:

Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP).

METHODS:

A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed.

RESULTS:

Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population.

CONCLUSIONS:

This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Canabinoides / Revisões Sistemáticas como Assunto Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: São Paulo med. j Assunto da revista: Cirurgia Geral / Ciˆncia / Ginecologia / MEDICINA / Medicina Interna / Obstetr¡cia / Pediatria / Sa£de Mental / Sa£de P£blica Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Canabinoides / Revisões Sistemáticas como Assunto Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: São Paulo med. j Assunto da revista: Cirurgia Geral / Ciˆncia / Ginecologia / MEDICINA / Medicina Interna / Obstetr¡cia / Pediatria / Sa£de Mental / Sa£de P£blica Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil